<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39382274</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>06</Day></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of &#x3b2;-lactams and the novel &#x3b2;-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales.</ArticleTitle><Pagination><StartPage>e0092424</StartPage><MedlinePgn>e0092424</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00924-24</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/aac.00924-24</ELocationID><Abstract><AbstractText>We aimed to investigate the activity of and mechanisms of resistance to cefiderocol and innovative &#x3b2;-lactam/&#x3b2;-lactamase inhibitor combinations in a nationwide collection of double-carbapenemase-producing Enterobacterales. In all, 57 clinical isolates co-producing two carbapenemases collected from Spanish hospitals during the period 2017-2022 were analyzed. Minimum inhibitory concentration (MIC) values for ceftazidime, ceftazidime/avibactam, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, cefiderocol, cefepime, cefepime/taniborbactam, cefepime/zidebactam, cefepime/nacubactam, imipenem, imipenem/relebactam, meropenem, meropenem/vaborbactam, meropenem/xeruborbactam, and meropenem/ANT3310 were determined by reference broth microdilution. Genetic drivers of resistance were analyzed by whole-genome sequencing (WGS). The collection covered nine carbapenemase associations: VIM + OXA-48 (21/57), NDM + OXA-48 (11/57), KPC + VIM (10/57), KPC + OXA-48 (6/57), IMP + OXA-48 (3/57), NDM + KPC (2/57), NDM + VIM (2/57), NDM + GES (1/57), and KPC + IMP (1/57). Ceftazidime/avibactam, imipenem/relebactam, and meropenem/vaborbactam were the least active options. Aztreonam/avibactam and aztreonam/nacubactam were active against the whole collection and yielded MIC<sub>50</sub>/MIC<sub>90</sub> values of &#x2264;0.25/0.5 mg/L and 1/2 mg/L, respectively. Cefepime/zidebactam (56/57 susceptible), meropenem/xeruborbactam (56/57 susceptible), cefepime/nacubactam (55/57 susceptible), and cefiderocol (53/57 susceptible) were also highly active, with MIC<sub>50</sub>/MIC<sub>90</sub> values ranging from &#x2264;0.25-2 mg/L to 2-4 mg/L, respectively. Meropenem/ANT3310 (MIC<sub>50</sub>/MIC<sub>90</sub> = 0.5/&#x2265;64 mg/L; 47/57 susceptible) and cefepime/taniborbactam (MIC<sub>50</sub>/MIC<sub>90</sub> = 0.5/16 mg/L; 44/57 susceptible) also retained high levels of activity, although they were affected by NDM-type enzymes in combination with porin deficiency. Our findings highlight that cefiderocol and combinations of &#x3b2;-lactams and the novel &#x3b2;-lactamase inhibitors avibactam, nacubactam, taniborbactam, zidebactam, xeruborbactam, and ANT3310 show promising activity against double-carbapenemase-producing Enterobacterales.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Blanco-Mart&#xed;n</LastName><ForeName>Tania</ForeName><Initials>T</Initials><Identifier Source="ORCID">0009-0003-1636-6429</Identifier><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a Cl&#xed;nica e Instituto de Investigaci&#xf3;n Biom&#xe9;dica A Coru&#xf1;a (INIBIC), Complexo Hospitalario Universitario A Coru&#xf1;a, A Coru&#xf1;a, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>L&#xf3;pez-Hern&#xe1;ndez</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratorio de Referencia para tipado molecular y detecci&#xf3;n de mecanismos de resistencia a antimicrobianos de Andaluc&#xed;a (PIRASOA). Unidad de Gesti&#xf3;n Cl&#xed;nica de Microbiolog&#xed;a y Enfermedades Infecciosas, Hospital Universitario Virgen Macarena. Instituto de Biomedicina de Sevilla (IBIS), CSIC, Universidad de Sevilla, Seville, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Aracil</LastName><ForeName>Bel&#xe9;n</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratorio de Referencia e Investigaci&#xf3;n en Resistencia a Antibi&#xf3;ticos e Infecciones relacionadas con la Asistencia Sanitaria, Centro Nacional de Microbiolog&#xed;a, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Pinto</LastName><ForeName>Luc&#xed;a</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a Cl&#xed;nica e Instituto de Investigaci&#xf3;n Biom&#xe9;dica A Coru&#xf1;a (INIBIC), Complexo Hospitalario Universitario A Coru&#xf1;a, A Coru&#xf1;a, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aja-Macaya</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a Cl&#xed;nica e Instituto de Investigaci&#xf3;n Biom&#xe9;dica A Coru&#xf1;a (INIBIC), Complexo Hospitalario Universitario A Coru&#xf1;a, A Coru&#xf1;a, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso-Garc&#xed;a</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a Cl&#xed;nica e Instituto de Investigaci&#xf3;n Biom&#xe9;dica A Coru&#xf1;a (INIBIC), Complexo Hospitalario Universitario A Coru&#xf1;a, A Coru&#xf1;a, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Pallares</LastName><ForeName>Salud</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a Cl&#xed;nica e Instituto de Investigaci&#xf3;n Biom&#xe9;dica A Coru&#xf1;a (INIBIC), Complexo Hospitalario Universitario A Coru&#xf1;a, A Coru&#xf1;a, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Pe&#xf1;a</LastName><ForeName>Luc&#xed;a</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a Cl&#xed;nica e Instituto de Investigaci&#xf3;n Biom&#xe9;dica A Coru&#xf1;a (INIBIC), Complexo Hospitalario Universitario A Coru&#xf1;a, A Coru&#xf1;a, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Outeda-Garc&#xed;a</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a Cl&#xed;nica e Instituto de Investigaci&#xf3;n Biom&#xe9;dica A Coru&#xf1;a (INIBIC), Complexo Hospitalario Universitario A Coru&#xf1;a, A Coru&#xf1;a, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-V&#xe1;zquez</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratorio de Referencia e Investigaci&#xf3;n en Resistencia a Antibi&#xf3;ticos e Infecciones relacionadas con la Asistencia Sanitaria, Centro Nacional de Microbiolog&#xed;a, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe1;zquez-Ucha</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a Cl&#xed;nica e Instituto de Investigaci&#xf3;n Biom&#xe9;dica A Coru&#xf1;a (INIBIC), Complexo Hospitalario Universitario A Coru&#xf1;a, A Coru&#xf1;a, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beceiro</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6340-7815</Identifier><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a Cl&#xed;nica e Instituto de Investigaci&#xf3;n Biom&#xe9;dica A Coru&#xf1;a (INIBIC), Complexo Hospitalario Universitario A Coru&#xf1;a, A Coru&#xf1;a, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascual</LastName><ForeName>&#xc1;lvaro</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Laboratorio de Referencia para tipado molecular y detecci&#xf3;n de mecanismos de resistencia a antimicrobianos de Andaluc&#xed;a (PIRASOA). Unidad de Gesti&#xf3;n Cl&#xed;nica de Microbiolog&#xed;a y Enfermedades Infecciosas, Hospital Universitario Virgen Macarena. Instituto de Biomedicina de Sevilla (IBIS), CSIC, Universidad de Sevilla, Seville, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bou</LastName><ForeName>Germ&#xe1;n</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-8837-0062</Identifier><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a Cl&#xed;nica e Instituto de Investigaci&#xf3;n Biom&#xe9;dica A Coru&#xf1;a (INIBIC), Complexo Hospitalario Universitario A Coru&#xf1;a, A Coru&#xf1;a, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>L&#xf3;pez-Cerero</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-8950-4384</Identifier><AffiliationInfo><Affiliation>Laboratorio de Referencia para tipado molecular y detecci&#xf3;n de mecanismos de resistencia a antimicrobianos de Andaluc&#xed;a (PIRASOA). Unidad de Gesti&#xf3;n Cl&#xed;nica de Microbiolog&#xed;a y Enfermedades Infecciosas, Hospital Universitario Virgen Macarena. Instituto de Biomedicina de Sevilla (IBIS), CSIC, Universidad de Sevilla, Seville, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Oteo-Iglesias</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratorio de Referencia e Investigaci&#xf3;n en Resistencia a Antibi&#xf3;ticos e Infecciones relacionadas con la Asistencia Sanitaria, Centro Nacional de Microbiolog&#xed;a, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Arca-Su&#xe1;rez</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4248-503X</Identifier><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a Cl&#xed;nica e Instituto de Investigaci&#xf3;n Biom&#xe9;dica A Coru&#xf1;a (INIBIC), Complexo Hospitalario Universitario A Coru&#xf1;a, A Coru&#xf1;a, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>GEMARA-SEIMC/CIBERINFEC Study Group on the activity and resistance mechanisms to new &#x3b2;-lactams and &#x3b2;-lactamase inhibitors (PROTECT)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PI23/00851</GrantID><Agency>MEC | Instituto de Salud Carlos III (ISCIII)</Agency><Country/></Grant><Grant><GrantID>PMP22/00092</GrantID><Agency>MEC | Instituto de Salud Carlos III (ISCIII)</Agency><Country/></Grant><Grant><GrantID>PI20/00686</GrantID><Agency>MEC | Instituto de Salud Carlos III (ISCIII)</Agency><Country/></Grant><Grant><GrantID>CM23/00095</GrantID><Agency>MEC | Instituto de Salud Carlos III (ISCIII)</Agency><Country/></Grant><Grant><GrantID>PI21/00704</GrantID><Agency>MEC | Instituto de Salud Carlos III (ISCIII)</Agency><Country/></Grant><Grant><GrantID>FI23/00074</GrantID><Agency>MEC | Instituto de Salud Carlos III (ISCIII)</Agency><Country/></Grant><Grant><GrantID>CM21/00076</GrantID><Agency>MEC | Instituto de Salud Carlos III (ISCIII)</Agency><Country/></Grant><Grant><GrantID>JR23/00036</GrantID><Agency>MEC | Instituto de Salud Carlos III (ISCIII)</Agency><Country/></Grant><Grant><GrantID>CM23/00104</GrantID><Agency>MEC | Instituto de Salud Carlos III (ISCIII)</Agency><Country/></Grant><Grant><GrantID>IN606A 2023/023</GrantID><Agency>Axencia Galega de Innovaci&#xf3;n (GAIN)</Agency><Country/></Grant><Grant><GrantID>IN606B 2022/009</GrantID><Agency>Axencia Galega de Innovaci&#xf3;n (GAIN)</Agency><Country/></Grant><Grant><GrantID>PI22/01212</GrantID><Agency>MEC | Instituto de Salud Carlos III (ISCIII)</Agency><Country/></Grant><Grant><GrantID>JR21/00026</GrantID><Agency>MEC | Instituto de Salud Carlos III (ISCIII)</Agency><Country/></Grant><Grant><GrantID>PI20/01212</GrantID><Agency>MEC | Instituto de Salud Carlos III (ISCIII)</Agency><Country/></Grant><Grant><GrantID>PI21/00704</GrantID><Agency>MEC | Instituto de Salud Carlos III (ISCIII)</Agency><Country/></Grant><Grant><GrantID>CB21/13/00055</GrantID><Agency>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Infecciosas (CIBERINFEC)</Agency><Country/></Grant><Grant><GrantID>CB21/13/00012</GrantID><Agency>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Infecciosas (CIBERINFEC)</Agency><Country/></Grant><Grant><GrantID>CB21/13/00095</GrantID><Agency>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Infecciosas (CIBERINFEC)</Agency><Country/></Grant><Grant><GrantID>IN607D 2021/12</GrantID><Agency>Axencia Galega de Innovaci&#xf3;n (GAIN)</Agency><Country/></Grant><Grant><GrantID>IN607A 2016/22</GrantID><Agency>Axencia Galega de Innovaci&#xf3;n (GAIN)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053961">Azabicyclo Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.2.6</RegistryNumber><NameOfSubstance UI="D001618">beta-Lactamases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065093">beta-Lactamase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.2.6</RegistryNumber><NameOfSubstance UI="C063912">carbapenemase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002511">Cephalosporins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006573">Heterocyclic Compounds, 1-Ring</NameOfSubstance></Chemical><Chemical><RegistryNumber>8IGQ156Z07</RegistryNumber><NameOfSubstance UI="C000707821">taniborbactam</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000624484">zidebactam</NameOfSubstance></Chemical><Chemical><RegistryNumber>SZ34OMG6E8</RegistryNumber><NameOfSubstance UI="D000097602">Cefiderocol</NameOfSubstance></Chemical><Chemical><RegistryNumber>832O37V7MZ</RegistryNumber><NameOfSubstance UI="C000608518">nacubactam</NameOfSubstance></Chemical><Chemical><RegistryNumber>7352665165</RegistryNumber><NameOfSubstance UI="C543519">avibactam</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001897">Boronic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>9M416Z9QNR</RegistryNumber><NameOfSubstance UI="D002442">Ceftazidime</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034242">Cyclooctanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>807PW4VQE3</RegistryNumber><NameOfSubstance UI="D000077723">Cefepime</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000595613">avibactam, ceftazidime drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001889">Borinic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>G2B4VE5GH8</RegistryNumber><NameOfSubstance UI="D001398">Aztreonam</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047090">beta-Lactams</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002264">Carboxylic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007769">Lactams</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="Y">Microbial Sensitivity Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053961" MajorTopicYN="Y">Azabicyclo Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001618" MajorTopicYN="Y">beta-Lactamases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="Y">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065093" MajorTopicYN="Y">beta-Lactamase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001426" MajorTopicYN="Y">Bacterial Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002511" MajorTopicYN="Y">Cephalosporins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006573" MajorTopicYN="Y">Heterocyclic Compounds, 1-Ring</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097602" MajorTopicYN="Y">Cefiderocol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001897" MajorTopicYN="N">Boronic Acids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002442" MajorTopicYN="N">Ceftazidime</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034242" MajorTopicYN="N">Cyclooctanes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077723" MajorTopicYN="N">Cefepime</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001889" MajorTopicYN="N">Borinic Acids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001398" MajorTopicYN="N">Aztreonam</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047090" MajorTopicYN="N">beta-Lactams</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073182" MajorTopicYN="N">Carbapenem-Resistant Enterobacteriaceae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004755" MajorTopicYN="N">Enterobacteriaceae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024901" MajorTopicYN="N">Drug Resistance, Multiple, Bacterial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002264" MajorTopicYN="N">Carboxylic Acids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007769" MajorTopicYN="N">Lactams</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterobacterales</Keyword><Keyword MajorTopicYN="N">antimicrobial resistance</Keyword><Keyword MajorTopicYN="N">carbapenemase</Keyword><Keyword MajorTopicYN="N">cefiderocol</Keyword><Keyword MajorTopicYN="N">double carbapenemase</Keyword><Keyword MajorTopicYN="N">&#x3b2;-lactamase</Keyword><Keyword MajorTopicYN="N">&#x3b2;-lactamase inhibitor</Keyword></KeywordList><CoiStatement>Merck Sharp &amp; Dohme (MSD) provided relebactam powder, and cefiderocol was provided by Shionoghi. Commercial suppliers did not exercise any control over the conduct or reporting of the research. J.C.V.-U. has received honoraria for lectures and/or presentations from MSD. G.B. has received funding and study materials from MSD, grants contracts from MSD, Pfizer, ABAC Therapeutics, and Roche, and consulting fees and honoraria for lectures and/or presentations from MSD, Shionogi, Pfizer, and Roche. J.A.-S. has received honoraria for lectures and/or presentations from MSD, Shionogi, Pfizer, Roche, and Advanz.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>6</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39382274</ArticleId><ArticleId IdType="pmc">PMC11539232</ArticleId><ArticleId IdType="doi">10.1128/aac.00924-24</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, Abudahab K, Goater R, Giani T, Errico G, et al. . 2019. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol 4:1919&#x2013;1929. doi:10.1038/s41564-019-0492-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-019-0492-8</ArticleId><ArticleId IdType="pmc">PMC7244338</ArticleId><ArticleId IdType="pubmed">31358985</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianco G, Boattini M, Comini S, Casale R, Iannaccone M, Cavallo R, Costa C. 2022. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era. Eur J Clin Microbiol Infect Dis 41:573&#x2013;580. doi:10.1007/s10096-022-04408-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-022-04408-5</ArticleId><ArticleId IdType="pmc">PMC8780048</ArticleId><ArticleId IdType="pubmed">35061145</ArticleId></ArticleIdList></Reference><Reference><Citation>Riccobono E, Salvetti S, Coppi M, Montenora I, Di Pilato V, Rossolini GM. 2023. Citrobacter freundii resistant to novel &#x3b2;-lactamase inhibitor combinations and cefiderocol, co-producing class A, B and D carbapenemases encoded by transferable plasmids. J Antimicrob Chemother 78:1677&#x2013;1682. doi:10.1093/jac/dkad150</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkad150</ArticleId><ArticleId IdType="pubmed">37207353</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson DL. 2024. Antibacterial agents active against Gram negative bacilli in phase I, II, or III clinical trials. Expert Opin Investig Drugs 33:371&#x2013;387. doi:10.1080/13543784.2024.2326028</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2024.2326028</ArticleId><ArticleId IdType="pubmed">38445383</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y-S, Chen P-Y, Chou P-C, Wang J-T. 2023. In vitro activities and inoculum effects of cefiderocol and aztreonam-avibactam against metallo-&#x3b2;-lactamase-producing Enterobacteriaceae. Microbiol Spectr 11:e0056923. doi:10.1128/spectrum.00569-23</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.00569-23</ArticleId><ArticleId IdType="pmc">PMC10269523</ArticleId><ArticleId IdType="pubmed">37154758</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Mart&#xed;n T, Alonso-Garc&#xed;a I, Gonz&#xe1;lez-Pinto L, Outeda-Garc&#xed;a M, Guijarro-S&#xe1;nchez P, L&#xf3;pez-Hern&#xe1;ndez I, P&#xe9;rez-V&#xe1;zquez M, Aracil B, L&#xf3;pez-Cerero L, Fraile-Ribot P, Oliver A, V&#xe1;zquez-Ucha JC, Beceiro A, Bou G, Arca-Su&#xe1;rez J, GEMARA/SEIMC-CIBERINFEC Study Group on the activity and resistance mechanisms to new &#x3b2;-lactams and &#x3b2;-lactamase inhibitors (PROTECT) . 2024. Activity of cefiderocol and innovative &#x3b2;-lactam/&#x3b2;-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double &#x3b2;-lactamases under high and low permeability conditions. Int J Antimicrob Agents 63:107150. doi:10.1016/j.ijantimicag.2024.107150</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2024.107150</ArticleId><ArticleId IdType="pubmed">38513748</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies DT, Leiris S, Zalacain M, Sprynski N, Castandet J, Bousquet J, Lozano C, Llanos A, Alibaud L, Vasa S, et al. . 2020. Discovery of ANT3310, a novel broad-spectrum serine &#x3b2;-lactamase inhibitor of the diazabicyclooctane class, which strongly potentiates meropenem activity against carbapenem-resistant Enterobacterales and Acinetobacter baumannii. J Med Chem 63:15802&#x2013;15820. doi:10.1021/acs.jmedchem.0c01535</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c01535</ArticleId><ArticleId IdType="pubmed">33306385</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise MG, Karlowsky JA, Mohamed N, Hermsen ED, Kamat S, Townsend A, Brink A, Soriano A, Paterson DL, Moore LSP, Sahm DF. 2024. Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018-2022. J Glob Antimicrob Resist 37:168&#x2013;175. doi:10.1016/j.jgar.2024.03.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgar.2024.03.020</ArticleId><ArticleId IdType="pubmed">38608936</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandfort M, Hans JB, Fischer MA, Reichert F, Cremanns M, Eisfeld J, Pfeifer Y, Heck A, Eckmanns T, Werner G, Gatermann S, Haller S, Pfennigwerth N. 2022. Increase in NDM-1 and NDM-1/OXA-48-producing Klebsiella pneumoniae in Germany associated with the war in Ukraine, 2022. Euro Surveill 27:2200926. doi:10.2807/1560-7917.ES.2022.27.50.2200926</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.50.2200926</ArticleId><ArticleId IdType="pmc">PMC9808319</ArticleId><ArticleId IdType="pubmed">36695468</ArticleId></ArticleIdList></Reference><Reference><Citation>Ljungquist O, Haldorsen B, P&#xf6;ntinen AK, Janice J, Josefsen EH, Elstr&#xf8;m P, Kacelnik O, Sundsfjord A, Samuelsen &#xd8;, Norwegian Study Group on CPE, Members of The Norwegian Study Group on CPE . 2023. Nationwide, population-based observational study of the molecular epidemiology and temporal trend of carbapenemase-producing Enterobacterales in Norway, 2015 to 2021. Euro Surveill 28:2200774. doi:10.2807/1560-7917.ES.2023.28.27.2200774</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.27.2200774</ArticleId><ArticleId IdType="pmc">PMC10370044</ArticleId><ArticleId IdType="pubmed">37410381</ArticleId></ArticleIdList></Reference><Reference><Citation>Emeraud C, Mahamat A, Jousset AB, Bernabeu S, Goncalves T, Pommier C, Girlich D, Birer A, Rodriguez C, Pawlotsky J-M, Naas T, Bonnin RA, Dortet L. 2023. Emergence and rapid dissemination of highly resistant NDM-14-producing Klebsiella pneumoniae ST147, France, 2022. Euro Surveill 28:2300095. doi:10.2807/1560-7917.ES.2023.28.42.2300095</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.42.2300095</ArticleId><ArticleId IdType="pmc">PMC10588306</ArticleId><ArticleId IdType="pubmed">37855905</ArticleId></ArticleIdList></Reference><Reference><Citation>Arca-Su&#xe1;rez J, Rodi&#xf1;o-Janeiro BK, P&#xe9;rez A, Guijarro-S&#xe1;nchez P, V&#xe1;zquez-Ucha JC, Cruz F, G&#xf3;mez-Garrido J, Alioto TS, &#xc1;lvarez-Tejado M, Gut M, et al. . 2022. Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing. Int J Antimicrob Agents 59:106456. doi:10.1016/j.ijantimicag.2021.106456</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2021.106456</ArticleId><ArticleId IdType="pubmed">34688835</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Garc&#xed;a M, Cabello M, Ponce-Alonso M, Herrador-G&#xf3;mez PM, Gioia F, Cobo J, Cant&#xf3;n R, Ruiz-Garbajosa P. 2024. First detection in Spain of NDM-1-producing Pseudomonas aeruginosa in two patients transferred from Ukraine to a university hospital. J Glob Antimicrob Resist 36:105&#x2013;111. doi:10.1016/j.jgar.2023.12.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgar.2023.12.022</ArticleId><ArticleId IdType="pubmed">38159724</ArticleId></ArticleIdList></Reference><Reference><Citation>Sader HS, Carvalhaes CG, Kimbrough JH, Mendes RE, Castanheira M. 2024. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022). Int J Antimicrob Agents 63:107113. doi:10.1016/j.ijantimicag.2024.107113</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2024.107113</ArticleId><ArticleId IdType="pubmed">38354826</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe1;zquez-Ucha JC, Alonso-Garcia I, Guijarro-S&#xe1;nchez P, Lasarte-Monterrubio C, &#xc1;lvarez-Fraga L, Cend&#xf3;n-Esteve A, Outeda M, Maceiras R, Pe&#xf1;a-Escolano A, Mart&#xed;nez-Guiti&#xe1;n M, Arca-Su&#xe1;rez J, Bou G, Beceiro A, GEMARA-SEIMC/REIPI Enterobacterales Study Group . 2023. Activity of aztreonam in combination with novel &#x3b2;-lactamase inhibitors against metallo-&#x3b2;-lactamase-producing Enterobacterales from Spain. Int J Antimicrob Agents 61:106738. doi:10.1016/j.ijantimicag.2023.106738</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2023.106738</ArticleId><ArticleId IdType="pubmed">36736925</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes MD, Taracila MA, Good CE, Bajaksouzian S, Rojas LJ, van Duin D, Kreiswirth BN, Jacobs MR, Haldimann A, Papp-Wallace KM, Bonomo RA. 2019. Nacubactam enhances meropenem activity against carbapenem-resistant Klebsiella pneumoniae producing KPC. Antimicrob Agents Chemother 63:e00432-19. doi:10.1128/AAC.00432-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00432-19</ArticleId><ArticleId IdType="pmc">PMC6658744</ArticleId><ArticleId IdType="pubmed">31182530</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Terrier C, Nordmann P, Poirel L. 2022. In vitro activity of aztreonam in combination with newly developed &#x3b2;-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-&#x3b2;-lactamases. J Antimicrob Chemother 78:101&#x2013;107. doi:10.1093/jac/dkac360</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkac360</ArticleId><ArticleId IdType="pubmed">36308322</ArticleId></ArticleIdList></Reference><Reference><Citation>Mushtaq S, Vickers A, Woodford N, Haldimann A, Livermore DM. 2019. Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae. J Antimicrob Chemother 74:953&#x2013;960. doi:10.1093/jac/dky522</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dky522</ArticleId><ArticleId IdType="pubmed">30590470</ArticleId></ArticleIdList></Reference><Reference><Citation>Livermore DM, Warner M, Mushtaq S, Woodford N. 2016. Interactions of OP0595, a novel triple-action diazabicyclooctane, with &#x3b2;-lactams against OP0595-resistant Enterobacteriaceae mutants. Antimicrob Agents Chemother 60:554&#x2013;560. doi:10.1128/AAC.02184-15</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02184-15</ArticleId><ArticleId IdType="pmc">PMC4704216</ArticleId><ArticleId IdType="pubmed">26552987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasarte-Monterrubio C, Guijarro-S&#xe1;nchez P, V&#xe1;zquez-Ucha JC, Alonso-Garcia I, Alvarez-Fraga L, Outeda M, Martinez-Guitian M, Pe&#xf1;a-Escolano A, Maceiras R, Lence E, Gonz&#xe1;lez-Bello C, Arca-Su&#xe1;rez J, Bou G, Beceiro A. 2023. Antimicrobial activity of cefiderocol against the carbapenemase-producing Enterobacter cloacae complex and characterization of reduced susceptibility associated with metallo-&#x3b2;-lactamase VIM-1. Antimicrob Agents Chemother 67:e0150522. doi:10.1128/aac.01505-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.01505-22</ArticleId><ArticleId IdType="pmc">PMC10190674</ArticleId><ArticleId IdType="pubmed">37195077</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, Dane A, Henkel T, CERTAIN-1 Study Team . 2024. Cefepime&#x2013;taniborbactam in complicated urinary tract infection. N Engl J Med 390:611&#x2013;622. doi:10.1056/NEJMoa2304748</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2304748</ArticleId><ArticleId IdType="pubmed">38354140</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Trout REL, Chu G-H, McGarry D, Jackson RW, Hamrick JC, Daigle DM, Cusick SM, Pozzi C, De Luca F, Benvenuti M, Mangani S, Docquier J-D, Weiss WJ, Pevear DC, Xerri L, Burns CJ. 2020. Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-&#x3b2;-lactamase inhibitor for carbapenem-resistant bacterial infections. J Med Chem 63:2789&#x2013;2801. doi:10.1021/acs.jmedchem.9b01518</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.9b01518</ArticleId><ArticleId IdType="pmc">PMC7104248</ArticleId><ArticleId IdType="pubmed">31765155</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe1;zquez-Ucha JC, Lasarte-Monterrubio C, Guijarro-S&#xe1;nchez P, Ovia&#xf1;o M, &#xc1;lvarez-Fraga L, Alonso-Garc&#xed;a I, Arca-Su&#xe1;rez J, Bou G, Beceiro A, GEMARA-SEIMC/REIPI Enterobacterales Study Group . 2022. Assessment of activity and resistance mechanisms to cefepime in combination with the novel &#x3b2;-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a multicenter collection of carbapenemase-producing&#xa0;Enterobacterales. Antimicrob Agents Chemother 66:e0167621. doi:10.1128/AAC.01676-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01676-21</ArticleId><ArticleId IdType="pmc">PMC8846464</ArticleId><ArticleId IdType="pubmed">34807754</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Terrier C, Gruenig V, Fournier C, Nordmann P, Poirel L. 2023. NDM-9 resistance to taniborbactam. Lancet Infect Dis 23:401&#x2013;402. doi:10.1016/S1473-3099(23)00069-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00069-5</ArticleId><ArticleId IdType="pubmed">36796395</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Terrier C, Nordmann P, Sadek M, Poirel L. 2023. In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates. J Antimicrob Chemother 78:1191&#x2013;1194. doi:10.1093/jac/dkad061</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkad061</ArticleId><ArticleId IdType="pmc">PMC10154122</ArticleId><ArticleId IdType="pubmed">36921067</ArticleId></ArticleIdList></Reference><Reference><Citation>Morinaka A, Tsutsumi Y, Yamada M, Suzuki K, Watanabe T, Abe T, Furuuchi T, Inamura S, Sakamaki Y, Mitsuhashi N, Ida T, Livermore DM. 2015. OP0595, a new diazabicyclooctane: mode of action as a serine &#x3b2;-lactamase inhibitor, antibiotic and &#x3b2;-lactam 'enhancer' J Antimicrob Chemother 70:2779&#x2013;2786. doi:10.1093/jac/dkv166</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkv166</ArticleId><ArticleId IdType="pubmed">26089439</ArticleId></ArticleIdList></Reference><Reference><Citation>Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA, Oliver A. 2017. WCK 5107 (Zidebactam) and WCK 5153&#xa0;are novel inhibitors&#xa0;of PBP2 showing potent &#x201c;&#x3b2;-lactam enhancer&#x201d; activity against Pseudomonas aeruginosa, including multidrug-resistant metallo-&#x3b2;-lactamase-producing high-risk clones. Antimicrob Agents Chemother 61:e02529-16. doi:10.1128/AAC.02529-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02529-16</ArticleId><ArticleId IdType="pmc">PMC5444176</ArticleId><ArticleId IdType="pubmed">28289035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun D, Tsivkovski R, Pogliano J, Tsunemoto H, Nelson K, Rubio-Aparicio D, Lomovskaya O. 2022. Intrinsic antibacterial activity of xeruborbactam in vitro: assessing spectrum and mode of action. Antimicrob Agents Chemother 66:e0087922. doi:10.1128/aac.00879-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.00879-22</ArticleId><ArticleId IdType="pmc">PMC9578396</ArticleId><ArticleId IdType="pubmed">36102663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomovskaya O, Castanheira M, Lindley J, Rubio-Aparicio D, Nelson K, Tsivkovski R, Sun D, Totrov M, Loutit J, Dudley M. 2023. In vitro potency of xeruborbactam in combination with multiple &#x3b2;-lactam antibiotics in comparison with other &#x3b2;-lactam/&#x3b2;-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum &#x3b2;-lactamase-producing Enterobacterales. Antimicrob Agents Chemother 67:e0044023. doi:10.1128/aac.00440-23</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.00440-23</ArticleId><ArticleId IdType="pmc">PMC10648875</ArticleId><ArticleId IdType="pubmed">37800963</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsivkovski R, Totrov M, Lomovskaya O. 2020. Biochemical characterization of QPX7728, a new ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases. Antimicrob Agents Chemother 64:e00130-20. doi:10.1128/AAC.00130-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00130-20</ArticleId><ArticleId IdType="pmc">PMC7269513</ArticleId><ArticleId IdType="pubmed">32152086</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Terrier C, Freire S, Viguier C, Findlay J, Nordmann P, Poirel L. 2024. Relative inhibitory activities of the broad-spectrum &#x3b2;-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-&#x3b2;-lactamases produced in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 68:e0157023. doi:10.1128/aac.01570-23</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.01570-23</ArticleId><ArticleId IdType="pmc">PMC11620488</ArticleId><ArticleId IdType="pubmed">38727224</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadek M, Bosch Duran J, Poirel L, Nordmann P. 2023. Impact of minor carbapenemases on susceptibility to novel &#x3b2;-lactam/&#x3b2;-lactamase inhibitor combinations and cefiderocol in&#xa0;Enterobacterales. Antimicrob Agents Chemother 67:e0007823. doi:10.1128/aac.00078-23</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.00078-23</ArticleId><ArticleId IdType="pmc">PMC10190267</ArticleId><ArticleId IdType="pubmed">37039645</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe1;zquez-Ucha JC, Seoane-Est&#xe9;vez A, Rodi&#xf1;o-Janeiro BK, Gonz&#xe1;lez-Bardanca M, Conde-P&#xe9;rez K, Mart&#xed;nez-Guiti&#xe1;n M, Alvarez-Fraga L, Arca-Su&#xe1;rez J, Lasarte-Monterrubio C, Gut M, et al. . 2021. Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales. J Antimicrob Chemother 76:1498&#x2013;1510. doi:10.1093/jac/dkab043</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkab043</ArticleId><ArticleId IdType="pubmed">33677560</ArticleId></ArticleIdList></Reference><Reference><Citation>Ca&#xf1;ada-Garc&#xed;a JE, Moure Z, Sola-Campoy PJ, Delgado-Valverde M, Cano ME, Gij&#xf3;n D, Gonz&#xe1;lez M, Gracia-Ahufinger I, Larrosa N, Mulet X, et al. . 2022. CARB-ES-19 multicenter study of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli from all Spanish provinces reveals interregional spread of high-risk clones such as ST307/OXA-48 and ST512/KPC-3. Front Microbiol 13:918362. doi:10.3389/fmicb.2022.918362</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.918362</ArticleId><ArticleId IdType="pmc">PMC9279682</ArticleId><ArticleId IdType="pubmed">35847090</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Hern&#xe1;ndez I, Delgado-Valverde M, Fern&#xe1;ndez-Cuenca F, L&#xf3;pez-Cerero L, Machuca J, Pascual &#xc1;. 2020. Carbapenemase-producing Gram-negative bacteria in&#xa0;Andalusia, Spain, 2014-2018. Emerg Infect Dis 26:2218&#x2013;2222. doi:10.3201/eid2609.191772</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2609.191772</ArticleId><ArticleId IdType="pmc">PMC7454067</ArticleId><ArticleId IdType="pubmed">32818413</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S. 2023. Ultrafast one-pass FASTQ data preprocessing, quality control, and deduplication using fastp. Imeta 2:e107. doi:10.1002/imt2.107</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/imt2.107</ArticleId><ArticleId IdType="pmc">PMC10989850</ArticleId><ArticleId IdType="pubmed">38868435</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotmistrovsky K, Agarwala R. 2011. BMTagger: Best Match Tagger for removing human reads from metagenomics datasets. Bioinformatics</Citation></Reference><Reference><Citation>Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput Biol 13:e1005595. doi:10.1371/journal.pcbi.1005595</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1005595</ArticleId><ArticleId IdType="pmc">PMC5481147</ArticleId><ArticleId IdType="pubmed">28594827</ArticleId></ArticleIdList></Reference><Reference><Citation>Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. 2015. CheckM: assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes. Genome Res 25:1043&#x2013;1055. doi:10.1101/gr.186072.114</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.186072.114</ArticleId><ArticleId IdType="pmc">PMC4484387</ArticleId><ArticleId IdType="pubmed">25977477</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen MV, Cosentino S, Lukjancenko O, Saputra D, Rasmussen S, Hasman H, Sicheritz-Pont&#xe9;n T, Aarestrup FM, Ussery DW, Lund O. 2014. Benchmarking of methods for genomic taxonomy. J Clin Microbiol 52:1529&#x2013;1539. doi:10.1128/JCM.02981-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02981-13</ArticleId><ArticleId IdType="pmc">PMC3993634</ArticleId><ArticleId IdType="pubmed">24574292</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwengers O, Jelonek L, Dieckmann MA, Beyvers S, Blom J, Goesmann A. 2021. Bakta: rapid and standardized annotation of bacterial genomes via alignment-free sequence identification. Microb Genom 7:000685. doi:10.1099/mgen.0.000685</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.000685</ArticleId><ArticleId IdType="pmc">PMC8743544</ArticleId><ArticleId IdType="pubmed">34739369</ArticleId></ArticleIdList></Reference><Reference><Citation>
Seemann T. Snippy: fast bacterial variant calling from NGS reads. Available from: https://github.com/tseemann/snippy</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>